NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/29/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization13,106 mln
Float205 mln
Earnings Date08/05/2026
EPS
3.02
Solid
P / E
16.75
Moderately valued
Piotroski F-Score
7
/ 9
Strong
Beneish M-Score
-2.56
Likely reliable
1-Year Forecast
49.65
Fairly priced
Relative Strength
28
/ 100
Underperforming
Business Description
Exelixis is a US-based cancer medicine company that develops and sells treatments for hard-to-treat cancers. Its main products are cabozantinib-based drugs, marketed as CABOMETYX and COMETRIQ, which are used to treat advanced kidney cancer and a rare form of thyroid cancer, respectively. The company also has a growing pipeline of experimental drugs targeting various cancers, and works alongside several major pharmaceutical partners to advance its research. Founded in 1994 and based in Alameda, California, Exelixis continues to expand its reach in oncology through both internal development and external collaborations.
